<DOC>
	<DOC>NCT00258739</DOC>
	<brief_summary>Primary objective: - To classify the 2 study groups, according to the tumoral response. Secondary objectives: - To evaluate the percentage of focused control per year. - To calculate the time until progression. - To evaluate the safety profile.</brief_summary>
	<brief_title>Docetaxel in Non Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Non small cell lung cancer confirmed by histology or by cytology. IIIB stage, except if existing pleural discharge, upper cava vein syndrome or supraclavicular affectation General stage 01 at the ECOG scale Loss of weight less than 5% in the 3 previous months from diagnose. Pulmonary function and gasometry results: FEV1 &gt; 30% or 1 l, DLCO (diffusing capacity of the lung for carbon monoxide) &gt; 30%, PCO2 &lt; 45 mmHg and PO2 &gt; 60 mmHg. Normal medullar function (hemoglobin &gt; 11 g/dl, total WBC &gt; 1,5 x 10^9/l, platelets &gt; 100 x 10^9/l) Appropriate renal and hepatic functions CTScan Anticonceptive method Available laboratory test (maximum 1 month before) Exclusion criteria: Pleural discharge, upper cava vein syndrome or supraclavicular affectation. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>